XBiotech Inc., incorporated on September 23, 2005, is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes.
The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease (which led to fast track designation from the Food and Drug Administration (FDA) to develop MABp1 as a therapy to reduce the need for re-intervention after treatment of peripheral vascular disease with angioplasty or other endovascular methods of treatment), type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). The Company completed enrollment in a double-blinded, placebo-controlled investigator-sponsored study for HS, an inflammatory skin disease of such severity that is often treated through surgical removal of lesions. The Company has completed enrollment in its Phase I/II study evaluating dosing, safety and efficacy of its antibody, 514G3. It is s using its True Human antibody technology to develop an oral monoclonal antibody against clostridium difficile (C. diff).
8201 E Riverside Dr Bldg 4 Ste 1
The company trades on NASDAQ exchange. The company headquarter is located in Texas, TX. The company was established in the 2005.| Ticker | XBIT |
| Long Name | XBiotech Inc. |
| Short Name | XBiotech |